Back to Journals » Clinical Ophthalmology » Volume 9

Bevacizumab for the treatment of a complicated posterior melanocytoma

Authors Urrets-Zavalia J, Crim N, Esposito E, Correa L, Gonzalez-Castellanos ME, Martinez D

Received 1 January 2015

Accepted for publication 2 February 2015

Published 6 March 2015 Volume 2015:9 Pages 455—459

DOI https://doi.org/10.2147/OPTH.S80152

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 2

Editor who approved publication: Dr Scott Fraser


Julio A Urrets-Zavalia,* Nicolas Crim,* Evangelina Esposito, Leandro Correa, M Eugenia Gonzalez-Castellanos, Dana Martinez

Department of Ophthalmology, University Clinic Reina Fabiola, Universidad Catolica de Cordoba, Cordoba, Argentina

*These authors contributed equally to this work

Purpose: To present a case of a complicated posterior melanocytoma that was successfully treated with intravitreal bevacizumab.
Case report: A 50-year-old Caucasian man was referred with sudden-onset metamorphopsia and decreased vision in his right eye over the course of the last 2 months. His best-corrected visual acuity was 20/80 and poorer than Jaeger 14 in the right eye, and 20/20 and Jaeger 1 in his left eye. In the right fundus, there was a melanocytic lesion occupying the inferotemporal quadrant of the optic disk, extending to the adjacent choroid inferiorly; optic nerve edema, superotemporal retinal vein dilatation, and subretinal fluid under the macula and nasal half of the posterior pole were observed, and a subretinal choroidal neovascularization complex was observed adjacent to the superotemporal margin of the optic disk, confirmed by fluorescein angiography, surrounded by a dense subretinal hemorrhage. Optical coherence tomography showed retinal edema and detachment of neurosensory retina. The patient was treated with three consecutive doses on a monthly basis of intravitreal 1.25 mg/0.05 mL bevacizumab. Visual acuity recovered rapidly, and at 4 months after treatment, it was 20/20 and Jaeger 1, with complete resolution of macular edema and subretinal fluid and hemorrhage. After 3 years of follow-up, best-corrected visual acuity remained stable, macular area was normal, and there was no evident optic nerve edema, retinal vein caliber and aspect were normal, and there was no significant change of the tumor. Fluorescein angiography only evidenced late staining of choroidal neovascularization scar, and optical coherence tomography showed a normal macular anatomy.
Conclusion: Intravitreal bevacizumab was effective in the treatment of choroidal neovascularization, optic nerve edema, venous dilatation, and local capillary telangiectasia, complicating an optic disk melanocytoma.

Keywords: optic disk melanocytoma, choroidal neovascularization, bevacizumab, retinal telangiectasia

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]